Advanced searches left 3/3

Carboplatin Phase - Europe PMC

Summarized by Plex Scholar
Last Updated: 03 October 2022

* If you want to update the article please login/register

Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.

In an open-label phase II trial in patients with metastatic TNBC, potentially through protection and prompt activation of immune function, a trilaciclib prior to gemcitabine plus carboplatin demonstrated significant rise in overall survival compared to GCb alone. The randomized, double-blind, placebo-controlled trial of phase III PRESERVE 2 will determine the effectiveness and safety of trilaciclib administered prior to GCB in patients with locally developed unresectable or metastatic TNBC.

Source link: https://europepmc.org/article/MED/36135712


Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.

BACKGROUND First-line treatment of nonsquamous non-small cell lung cancer has undergone a paradigm shift toward platinum combination therapy alongside immune checkpoint inhibitors. However, phase III trials of cytotoxic chemotherapy and ICIs have only included patients with maintained organ function, not those with renal impairment. Discussion If the research shows that carboplatin/nab-paclitaxel/atezolizumab's efficacy and safety, then this combination therapy may be a treatment option for nonsquamous NSCLC patients with impaired renal function.

Source link: https://europepmc.org/article/MED/36076179

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions